Repository logo
 

Resistance and resilience to Alzheimer's disease in Down syndrome.

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Due to the high prevalence of Alzheimer's disease (AD) in adults with Down syndrome (DS), trisomy 21 is now considered a genetic form of AD (DSAD). A better understanding of factors that can prevent or delay AD is vital to improve outcomes for adults with DS. In this narrative review, we apply AD and cognitive aging research frameworks to study resistance and resilience in DSAD. Given the variability in the timing of pathology and symptoms, we discuss the evidence supporting the role of genetic, biological, socio-behavioral, lifestyle, and environmental factors in resistance and resilience to DSAD. We also consider how co-occurring health conditions in DS may influence resistance and resilience, and how methods from AD research can be applied to DSAD. Ultimately, this framework aims to guide future research and translate findings into clinical interventions to improve outcomes in DSAD. Highlights Definitions of resistance and resilience in the genetic form of Alzheimer's disease (DSAD) are proposed for guiding the field. Variability in the timing of AD pathology and symptoms suggests the potential for resistance and resilience mechanisms in DSAD. Genetic, biological, socio-behavioral, lifestyle, and environmental factors have the potential to build resistance or resilience in DSAD. Future research will require longitudinal and experimental designs, life course approaches, and large cohort studies.

Description

Publication status: Published


Funder: Una Manera de Hacer Europa


Funder: Department de Salut de la Generalitat de Catalunya


Funder: Fondo de Investigaciones Sanitario


Funder: University of Nebraska, and Central States Center for Agricultural Safety and Health


Funder: Fondo de Investigaciones Sanitario, Carlos III Health Institute


Funder: Fondo Europeo de Desarrollo Regional, Una Manera de Hacer Europa, Department de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca I Innovació en Salut


Funder: European Union; doi: http://dx.doi.org/10.13039/501100000780


Funder: Alzheimer's Society United Kingdom


Funder: Jerome Lejeune Foundation; doi: http://dx.doi.org/10.13039/100007353


Funder: Spanish Ministry of Science and Innovation, European Social Fund—State Research Agency

Journal Title

Alzheimers Dement

Conference Name

Journal ISSN

1552-5260
1552-5279

Volume Title

21

Publisher

Wiley

Rights and licensing

Except where otherwised noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Sponsorship
European Social Fund—State Research Agency (RYC2018‐026053‐I, PID2019‐111514RA‐I00, PID2023‐15333620B‐100)
Barcelona City Council, Fundació La Caixa (21S09060, 23S06157‐001)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2018/15167)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (302527/2022‐2)
National Institutes of Health (R01AG079142, DP2AG082342, K01AG084816, R21AG075643, R61 HD100973, R01AG066159, R21AG075643, K99AG083063, AARG21850839, U19AG068054, RF1AG079519, R00AG065506, P30AG066519, RF1AG079519, RF1AG060472, U19AG068054, P30AG066519, 1R01AG070028, U19AG033655, P50AG005146, R01AG056850, R21AG056974, R01AG061566, R01AG081394, R61AG066543, U01AG024904)
Jerome Lejeune Foundation, Alzheimer's Society United Kingdom (ASPG213)
MRC Program Grant (MR/N029941/1)
Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP‐DOW‐2020‐151)
Pla Estratègic de Recerca I Innovació en Salut (SLT006/17/00119)
Salud Carlos III Sara Borrell (SBCD23/00235, CP20/00038)
Carlos III Health Institute (INT21/00073, PI20/01473, PI23/01786, PI22/00307)
Alzheimer's Association (AARG2019‐AARG‐644641, 23AARFD‐1022715, 23AARF‐1026796, AARG‐22‐923680)